艾达利穆马布在严重反复性状液硬化症和状液平症中使用
Ashling Courtney, Sarah Rose Adamson, Emma Veysey1
1Vulvar Disorders and Dermatology Unit, The Royal Women's Hospital, Parkville, Victoria, Australia.
Journal of lower genital tract disease
|December 9, 2024
概括
皮下注射的阿达利穆马布对严重的状样硬化和状样平坦有前途,改善了生活质量. 这种治疗耐受性很好,并在一个小的病例系列中证明了临床益处.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- Vulvar lichen sclerosus (VLS) 和 vulvar lichen planus (VLP) 是慢性炎症性皮肤病,严重影响生活质量.
- 由于有限的FDA批准的全身疗法,严重的VLS/VLP病例存在管理挑战.
- 作为TNF-α抑制剂的Adalimumab正在研究其针对VLS/VLP的炎症途径的潜力.
研究的目的:
- 评估严重,耐火性VLS和/或VLP患者的人口统计特征,疾病特征和治疗结果,这些患者接受了皮下阿达利姆巴治疗.
- 评估阿达利穆马布在治疗这些慢性状况方面的疗效和耐受性.
主要方法:
- 一个由8名VLS和/或VLP患者组成的病例系列,在第三级转诊诊所接受皮下阿达利穆马布治疗.
- 使用了患者报告的结果指标 (PROM),包括部生活质量指数 (VLQI) 和/疼痛量表.
- 临床严重程度被皮肤科医生客观地评估.
主要成果:
- 在8名患者中,6名患者耐受性良好,治疗持续时间至少为9个月.
- 在6名患者的皮肤症状和PROM,包括VLQI得分显著改善.
- 在所有参与者治疗期间,阴道的结构变化在治疗期间保持稳定.
结论:
- 皮下阿达利穆马布可能是严重,耐火性VLS和VLP的可行的治疗选择,显示出显著的PROM改善.
- 阿达利穆马布的临床益处表明,它针对涉及VLS和VLP病变的关键炎症途径.
- 需要进一步进行受控试验,以确认这种具有挑战性的患者群体的疗效,安全性,并确定反应的预测因子.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
142
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:29Inflammatory Bowel Disease IV: Pharmacological Management
112
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
112
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115